alexa Cancer Genomics in the Era of Checkpoint Inhibition: Biomarkers to Predict Tumor Response to Checkpoint Inhibition Therapy | OMICS International| Abstract
ISSN: 1747-0862

Journal of Molecular and Genetic Medicine
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Mini Review   
  • J Mol Genet Med 2017, Vol 11(4): 292
  • DOI: 10.4172/1747-0862.1000292

Cancer Genomics in the Era of Checkpoint Inhibition: Biomarkers to Predict Tumor Response to Checkpoint Inhibition Therapy

Kim S*
Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, , Houston, TX 77030, USA
*Corresponding Author : Kim S, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1465, Houston, Texas 77030, USA, Tel: 713-745-4516, Fax: 713-563-4491, Email: [email protected]

Received Date: Sep 26, 2017 / Accepted Date: Oct 06, 2017 / Published Date: Oct 10, 2017

Abstract

With their ground-breaking clinical success, immune checkpoint inhibitors (ICIs) have opened a new chapter in cancer treatment; however, not all patients have a response to ICI treatment. Current approaches to maximizing the efficacy of ICI treatment include combining it with conventional cancer treatments and identifying biomarkers that accurately predict tumor responses to ICI agents. This mini-review introduces genomic determinants of ICI efficacy and directions for future immunogenomic studies in the era of checkpoint inhibition.

Keywords: Antitumor immunity; Cytotoxic; Antibodies; Lung cancer, Kidney cancer, Hodgkin disease

Citation: Kim S (2017) Cancer Genomics in the Era of Checkpoint Inhibition: Biomarkers to Predict Tumor Response to Checkpoint Inhibition Therapy. J Mol Genet Med 11: 292 Doi: 10.4172/1747-0862.1000292

Copyright: © 2017 Kim S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 3088
  • [From(publication date): 0-2017 - Dec 15, 2019]
  • Breakdown by view type
  • HTML page views: 3002
  • PDF downloads: 86
Top